News
Iran's Drug Expenditure to Grow by an Average Of 14.8% Year-On-Year to Reach IRR34, 494bn (US$3.52bn) By the End Of 2012
DUBLIN, Ireland-(Business Wire)-October 3, 2008 - Research and Markets (http://www.researchandmarkets.com/research/ce6228/iran_pharmaceutica) has announced the addition of the "Iran Pharmaceuticals and Healthcare Report Q3 2008" report to their offering.
The Iran Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Iran's pharmaceuticals and healthcare industry.
Iran’s pharmaceutical market was estimated to be worth IRR17,278bn (US$1.87bn). Over the five-year forecast period, we expect drug expenditure to grow by an average of 14.8% year-on-year (y-o-y) in local currency over the forecast period to reach IRR34,494bn (US$3.52bn) by the end of 2012. The high nominal growth is largely a result of high inflation, which we expect to average 18% y-o-y over the forecast period. Indeed, it masks our relatively poor assessment of the growth prospects in the market, which should be beaten by both inflation and nominal GDP growth.
Despite relatively gloomy prospects for value growth, we expect strong volume growth in the market on account of an expanding population and strong government sponsored healthcare programmes. Indeed, we expect the use of generics to increase further over the forecast period, gaining a further three percentage points (pps) in terms of drug market share between 2008 and 2012. In the updated Business Environment Ratings for Q308, Iran is ranked in ninth position out of 13 countries in the Middle East and Africa (MEA). Its large pharmaceutical market provides opportunities for drugmakers. However, a risky regulatory environment creates challenges for companies operating in Iran, especially foreign drugmakers.
While foreign direct investment (FDI) in Iran’s pharmaceutical industry remains limited due to political uncertainty, a number of domestic drugmakers have demonstrated they are still capable of developing and manufacturing relatively sophisticated products. In May 2008, Exir began producing hepatitis C treatment interferon gamma under the brand name Gamma Immunex. Iran’s healthcare system is strong in terms of population coverage – with at least 90% of the population having access to healthcare. Rural access remains patchy at present, however strong investment in healthcare infrastructure, including 5,000 additional hospital beds in the country during 2006 and 2007 and a commitment to increase the number of doctors serving in rural areas should boost access to healthcare further over the forecast period.
| Key Topics Covered: |
| Â |
| Executive Summary |
| SWOT Analysis |
| Table: Iran Pharmaceuticals And Healthcare Industry SWOT |
| Iran Political SWOT |
| Iran Economic SWOT |
| Iran Business Environment SWOT |
| Business Environment Ranking |
| Iran - Business Environment Ranking |
| Table: Pharmaceutical Business Environment Ratings |
| Limits Of Potential Returns |
| Risks To Realisation Of Returns |
| Market Summary |
| Regulatory Regime |
| Registration Of Imports |
| Generic Registration |
| Intellectual Property (IP) Regime |
| Intellectual Property Disputes |
| Counterfeit Medicines |
| Pricing And Reimbursement |
| Industry Developments |
| Health Status |
| HIV/AIDS Situation |
| Iran HIV/AIDS Prevalence |
| Healthcare Sector |
| Primary Care |
| Secondary Care |
| Retail Pharmacies |
| Health Insurance |
| Regional Developments |
| International Collaboration |
| Pharmaceutical Industry |
| Traditional Herbal Remedies |
| Recent Company Activity |
| Research And Development |
| International Co-operation |
| Industry Forecast Scenario |
| Overall Market Forecast |
| Table: Drug Expenditure Forecasts |
| Key Growth Factors - Industry |
| Table: Health Expenditure Forecasts |
| Key Growth Factors - Macroeconomic |
| Table: Iran - Economic Activity |
| Prescription Market Forecast |
| Table: Prescription Drug Market Forecast (US$bn unless otherwise |
| stated) |
| OTC Market Forecast |
| Table: OTC Market Data Forecasts (US$bn unless otherwise stated) |
| Generics And Patented Market Forecast |
| Table: Generics And Patented Market Forecasts |
| Medical Device Market Forecast |
| Iran Medical Device Market Forecast |
| Import/Export Market Forecast |
| Table: Pharmaceutical Trade Indicators (US$mn) |
| Other Healthcare Data Forecasts |
| Table: Other Health Indicators |
| Key Risks To Our Forecast Scenario |
| Competitive Landscape |
| Company Profiles |
| Multinationals |
| Novartis |
| Merck & Co |
| Pfizer |
| GlaxoSmithKline |
| Sanofi-Aventis |
| Indigenous Companies |
| Darou Pakhsh |
| Caspian Tamin Pharmaceutical Company |
| Pharmieco |
| Pars Darou |
| Zahravi |
| Amin |
| Sina Darou Pharmaceutical Company |
| Exir Pharmaceuticals |
| Our Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
| Â |
| Companies Mentioned: |
| Â |
| -Novartis |
| -Merck & Co |
| -Pfizer |
| -GlaxoSmithKline |
| -Sanofi-Aventis |
| -Darou Pakhsh |
| -Caspian Tamin Pharmaceutical Company |
| -Pharmieco |
| -Pars Darou |
| -Zahravi |
| -Amin |
| -Sina Darou Pharmaceutical Company |
| -Exir Pharmaceuticals |
For more information visit http://www.researchandmarkets.com/research/ce6228/iran_pharmaceutica
 |
 |
 |
|
||
 |
|
 |
|
||
Search Our News Using Google Search
Can't find what you want? Try using Google:
